Overexpression of NPRL2 in colon cancer cells increased the sensitivity to a topoisomerase I inhibitor, irinotecan (CPT-11), by activating the DNA damage checkpoints [89]. The gene discussed is NPRL2; the disease is colonic neoplasm.